Moderna, Inc. — Director's Dealing 2021

Feb 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-02-22

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-22	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2021-02-22	Common Stock	S	263	$159.32	Disposed	4737	Direct
2021-02-22	Common Stock	S	100	$160.38	Disposed	4637	Direct
2021-02-22	Common Stock	S	800	$162.47	Disposed	3837	Direct
2021-02-22	Common Stock	S	1100	$163.57	Disposed	2737	Direct
2021-02-22	Common Stock	S	300	$164.60	Disposed	2437	Direct
2021-02-22	Common Stock	S	1000	$165.95	Disposed	1437	Direct
2021-02-22	Common Stock	S	700	$166.82	Disposed	737	Direct
2021-02-22	Common Stock	S	356	$168.00	Disposed	381	Direct
2021-02-22	Common Stock	S	281	$168.90	Disposed	100	Direct
2021-02-22	Common Stock	S	100	$169.81	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-22	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-02-23	Common Stock (5000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.13 to $159.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.97 to $162.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.19 to $164.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.26 to $165.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.44 to $166.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.47 to $167.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.72 to $168.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.75 to $169.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.